345 related articles for article (PubMed ID: 32057736)
1. Alteration of purinergic signaling in diabetes: Focus on vascular function.
Zhou R; Dang X; Sprague RS; Mustafa SJ; Zhou Z
J Mol Cell Cardiol; 2020 Mar; 140():1-9. PubMed ID: 32057736
[TBL] [Abstract][Full Text] [Related]
2. Diabetes and hypertension: Pivotal involvement of purinergic signaling.
Reichert KP; Castro MFV; Assmann CE; Bottari NB; Miron VV; Cardoso A; Stefanello N; Morsch VMM; Schetinger MRC
Biomed Pharmacother; 2021 May; 137():111273. PubMed ID: 33524787
[TBL] [Abstract][Full Text] [Related]
3. Divergent regulatory roles of extracellular ATP in the degranulation response of mouse bone marrow-derived mast cells.
Yoshida K; Ito M; Matsuoka I
Int Immunopharmacol; 2017 Feb; 43():99-107. PubMed ID: 27988461
[TBL] [Abstract][Full Text] [Related]
4. Purinergic interplay between erythrocytes and platelets in diabetes-associated vascular dysfunction.
Zhou Z
Purinergic Signal; 2021 Dec; 17(4):705-712. PubMed ID: 34410591
[TBL] [Abstract][Full Text] [Related]
5. Aberrant circulating levels of purinergic signaling markers are associated with several key aspects of peripheral atherosclerosis and thrombosis.
Jalkanen J; Yegutkin GG; Hollmén M; Aalto K; Kiviniemi T; Salomaa V; Jalkanen S; Hakovirta H
Circ Res; 2015 Mar; 116(7):1206-15. PubMed ID: 25645301
[TBL] [Abstract][Full Text] [Related]
6. Conversion of extracellular ATP into adenosine: a master switch in renal health and disease.
Dwyer KM; Kishore BK; Robson SC
Nat Rev Nephrol; 2020 Sep; 16(9):509-524. PubMed ID: 32641760
[TBL] [Abstract][Full Text] [Related]
7. Ankylosing spondylitis monocyte-derived macrophages express increased level of A
Akhtari M; Zargar SJ; Mahmoudi M; Vojdanian M; Rezaeimanesh A; Jamshidi A
Clin Rheumatol; 2018 Jun; 37(6):1589-1595. PubMed ID: 29524036
[TBL] [Abstract][Full Text] [Related]
8. Emerging Roles of Purinergic Signaling in Diabetes.
Fotino C; Dal Ben D; Adinolfi E
Med Chem; 2018; 14(5):428-438. PubMed ID: 29485002
[TBL] [Abstract][Full Text] [Related]
9. CD39 and CD73 in the aortic valve-biochemical and immunohistochemical analysis in valve cell populations and its changes in valve mineralization.
Kaniewska-Bednarczuk E; Kutryb-Zajac B; Sarathchandra P; Pelikant-Malecka I; Sielicka A; Piotrowska I; Slominska EM; Chester AH; Yacoub MH; Smolenski RT
Cardiovasc Pathol; 2018; 36():53-63. PubMed ID: 30056298
[TBL] [Abstract][Full Text] [Related]
10. Endothelial cells cope with hypoxia-induced depletion of ATP via activation of cellular purine turnover and phosphotransfer networks.
Losenkova K; Zuccarini M; Helenius M; Jacquemet G; Gerasimovskaya E; Tallgren C; Jalkanen S; Yegutkin GG
Biochim Biophys Acta Mol Basis Dis; 2018 May; 1864(5 Pt A):1804-1815. PubMed ID: 29514048
[TBL] [Abstract][Full Text] [Related]
11. Purinergic signaling in kidney disease.
Menzies RI; Tam FW; Unwin RJ; Bailey MA
Kidney Int; 2017 Feb; 91(2):315-323. PubMed ID: 27780585
[TBL] [Abstract][Full Text] [Related]
12. Ectonucleotidases in Intestinal and Hepatic Inflammation.
Vuerich M; Robson SC; Longhi MS
Front Immunol; 2019; 10():507. PubMed ID: 30941139
[TBL] [Abstract][Full Text] [Related]
13. Purinergic signaling in the pancreas and the therapeutic potential of ecto-nucleotidases in diabetes.
Cieślak M; Roszek K
Acta Biochim Pol; 2014; 61(4):655-62. PubMed ID: 25522227
[TBL] [Abstract][Full Text] [Related]
14. Pharmacological blockade of the CD39/CD73 pathway but not adenosine receptors augments disease in a humanized mouse model of graft-versus-host disease.
Geraghty NJ; Watson D; Sluyter R
Immunol Cell Biol; 2019 Jul; 97(6):597-610. PubMed ID: 30957314
[TBL] [Abstract][Full Text] [Related]
15. Purinergic signaling: a potential therapeutic target for ischemic stroke.
Wang L; Li YJ; Yang X; Yang B; Zhang X; Zhang J; Zhang Q; Cheng XD; Wang JH; Yu NW
Purinergic Signal; 2023 Mar; 19(1):173-183. PubMed ID: 36370253
[TBL] [Abstract][Full Text] [Related]
16. Altered E-NTPDase/E-ADA activities and CD39 expression in platelets of sickle cell anemia patients.
Castilhos LG; Doleski PH; Adefegha SA; Becker LV; Ruchel JB; Leal DB
Biomed Pharmacother; 2016 Apr; 79():241-6. PubMed ID: 27044834
[TBL] [Abstract][Full Text] [Related]
17. Adenosine and adenosine receptors in colorectal cancer.
Hajizadeh F; Masjedi A; Heydarzedeh Asl S; Karoon Kiani F; Peydaveisi M; Ghalamfarsa G; Jadidi-Niaragh F; Sevbitov A
Int Immunopharmacol; 2020 Oct; 87():106853. PubMed ID: 32755765
[TBL] [Abstract][Full Text] [Related]
18. CD39 limits P2X7 receptor inflammatory signaling and attenuates sepsis-induced liver injury.
Savio LEB; de Andrade Mello P; Figliuolo VR; de Avelar Almeida TF; Santana PT; Oliveira SDS; Silva CLM; Feldbrügge L; Csizmadia E; Minshall RD; Longhi MS; Wu Y; Robson SC; Coutinho-Silva R
J Hepatol; 2017 Oct; 67(4):716-726. PubMed ID: 28554875
[TBL] [Abstract][Full Text] [Related]
19. Adenosine metabolism in the vascular system.
Yegutkin GG
Biochem Pharmacol; 2021 May; 187():114373. PubMed ID: 33340515
[TBL] [Abstract][Full Text] [Related]
20. Purinergic Dysfunction in Pulmonary Arterial Hypertension.
Cai Z; Tu L; Guignabert C; Merkus D; Zhou Z
J Am Heart Assoc; 2020 Sep; 9(18):e017404. PubMed ID: 32867554
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]